Literature DB >> 22228247

Effect of ambiguous hemochromatosis gene test results on physician utilization.

Mark Speechley1, David Alter, Helen Guo, Helen Harrison, Paul C Adams.   

Abstract

BACKGROUND: Genetic test results may be available to greater numbers of people through genetic screening projects and other means. The effects of widespread genetic testing and notification of genetic test results, particularly added costs through increased physician utilization, have not been clearly established.
METHODS: A primary care-based cohort of 20,306 participants (Hemochromatosis and Iron Overload Study, Ontario site) were tested for the C282Y and H63D mutations of the HFE gene and for abnormal serum ferritin (SF) and transferrin saturation levels. The primary outcome variable was the total number of physician claims per patient after genetic test notification by mail. Multiple Poisson regression was used to adjust for age, sex, baseline SF, diagnoses of arthritis, diabetes, heart failure and impotence, self-rated health, and the number of claims during the 12 months before notification of results. The reference group had no HFE mutations (wild type) and normal transferrin saturation/SF values.
RESULTS: Participants with an ambiguous hemochromatosis gene test and normal iron levels had statistically significantly higher average physician utilization of 3.0%. Participants with HFE mutations (excluding C282Y homozygotes) and elevated iron values showed a 6% increase in physician utilization.
CONCLUSIONS: The health effects, if any, of increased utilization in heterozygotes or those with mild ferritin elevations are unknown but are unlikely to be large at the population level. Ambiguous genetic test results are associated with increased physician service use and should be considered when assessing the complete societal costs of widespread genetic testing.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22228247      PMCID: PMC3440764          DOI: 10.1097/MLR.0b013e318245a06e

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  8 in total

Review 1.  The annual Pap test: a dubious policy success.

Authors:  A M Foltz; J L Kelsey
Journal:  Milbank Mem Fund Q Health Soc       Date:  1978

2.  Impact of direct-to-consumer advertising for hereditary breast cancer testing on genetic services at a managed care organization: a naturally-occurring experiment.

Authors:  Judy Mouchawar; Sharon Hensley-Alford; Suzanne Laurion; Jennifer Ellis; Alanna Kulchak-Rahm; Melissa L Finucane; Richard Meenan; Lisen Axell; Rebecca Pollack; Debra Ritzwoller
Journal:  Genet Med       Date:  2005-03       Impact factor: 8.822

3.  Hemochromatosis and Iron Overload Screening (HEIRS) study design for an evaluation of 100,000 primary care-based adults.

Authors:  Christine E McLaren; James C Barton; Paul C Adams; Emily L Harris; Ronald T Acton; Nancy Press; David M Reboussin; Gordon D McLaren; Phyliss Sholinsky; Ann P Walker; Victor R Gordeuk; Catherine Leiendecker-Foster; Fitzroy W Dawkins; John H Eckfeldt; Beverly G Mellen; Mark Speechley; Elizabeth Thomson
Journal:  Am J Med Sci       Date:  2003-02       Impact factor: 2.378

4.  Hemochromatosis and iron-overload screening in a racially diverse population.

Authors:  Paul C Adams; David M Reboussin; James C Barton; Christine E McLaren; John H Eckfeldt; Gordon D McLaren; Fitzroy W Dawkins; Ronald T Acton; Emily L Harris; Victor R Gordeuk; Catherine Leiendecker-Foster; Mark Speechley; Beverly M Snively; Joan L Holup; Elizabeth Thomson; Phyliss Sholinsky
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

5.  Results communication and patient education after screening for possible hemochromatosis and iron overload: experience from the HEIRS Study of a large ethnically and linguistically diverse group.

Authors:  Ann P Walker; Diane C Tucker; Mark A Hall; Kurt Lohman; Helen Harrison; Barbara W Harrison; Jacob Reiss; Ronald T Acton; Paul C Adams; Sharmin Diaz; Joan Holup; Elizabeth Thomson; Shellie D Ellis; Christine E McLaren
Journal:  Genet Med       Date:  2007-11       Impact factor: 8.822

6.  Screening for hemochromatosis and iron overload: satisfaction with results notification and understanding of mailed results in unaffected participants of the HEIRS study.

Authors:  Helen F Harrison; Barbara W Harrison; Ann P Walker; Kurt Lohman; Shellie D Ellis; Mark A Hall; Jacob Reiss; Paul C Adams; Joan Holup; Ronald T Acton; Thomas Bent; Charles Rivers; Margaret Fadojutimi-Akinsiku
Journal:  Genet Test       Date:  2008-12

7.  Impact of hemochromatosis screening in patients with indeterminate results: the hemochromatosis and iron overload screening study.

Authors:  Roger T Anderson; Lari Wenzel; Ann P Walker; Andrea Ruggiero; Ronald T Acton; Mark A Hall; Diane C Tucker; Elizabeth Thomson; Barbara Harrison; Edmund Howe; Joan Holup; Catherine Leiendecker-Foster; Tara Power; Paul Adams
Journal:  Genet Med       Date:  2006-11       Impact factor: 8.822

  8 in total
  3 in total

1.  Personalized medicine for osteoarthritis: where are we now?

Authors:  Allen Dale Sawitzke
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-04       Impact factor: 5.346

2.  H63D genotying for hemochromatosis: helper or hindrance?

Authors:  Paul C Adams
Journal:  Can J Gastroenterol Hepatol       Date:  2014-04

3.  Insufficient referral for genetic counseling in the management of hereditary haemochromatosis in portugal: a study of perceptions of health professionals requesting HFE genotyping.

Authors:  Bruna Leandro; Milena Paneque; Jorge Sequeiros; Graça Porto
Journal:  J Genet Couns       Date:  2014-01-08       Impact factor: 2.537

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.